Dsm-firmenich Ag · EURONEXT:DSFIR

Dsm-firmenich — Q1 2025 Earnings Presentation

11 slides from Dsm-firmenich's earnings presentation, Apr 30, 2025

  1. Slide 1: Presentation to Investors: Q1 2025 trading update

    Presentation to Investors Q1 2025 trading update April 30, 2025

  2. Slide 2: Highlights Q1 2025

    Highlights Q1 2025 • Good start to the year with strong organic sales and earnings growth • Progressing well on 2025 strategic plan Sales Organic Sales Growth €3,274m +8% • Sale of Feed Enzymes business for €1.5 billion announced • Animal Nutrition & Health exit process advancing as +7% planned • €1

  3. Slide 3: Q1 2025 Group financials

    Q1 2025 Group financials • Strong 8% organic sales growth with all businesses positively contributing, driving a further improvement in financial performance Q1 2025 sales development ✓ P&B: strong growth in Perfumery, and weak performance in Beauty due to suncare 4% €3,274m 4% ✓ TTH: strong perform

  4. Slide 4: Q1 2025 Perfumery & Beauty

    Q1 2025 Perfumery & Beauty Q1 2025 sales development • Perfumery delivered a strong, high-single digit organic sales growth despite a tough prior-year comparison €986m 1% 3% €1,015m ✓ Very strong demand for Fine Fragrances (1%) ✓ Good demand for Consumer Fragrance ✓ Strong demand for Ingredients Act

  5. Slide 5: Q1 2025 Taste, Texture & Health

    Q1 2025 Taste, Texture & Health Q1 2025 sales development • Strong start to the year delivering 7% organic sales growth 7% 0% €851m fully driven by higher volumes in both Taste and Ingredients €798m 1% (1%) Solutions ✓ Supported by 2% volume growth from sales synergies ✓ Market conditions remained s

  6. Slide 6: Q1 2025 Health, Nutrition & Care

    Q1 2025 Health, Nutrition & Care Q1 2025 sales development • Strong quarter with 7% organic sales growth, on 8% higher volumes 0% 8% €528m €526m ✓ Dietary Supplements saw continued recovery, with (1%) strong growth in algal lipid solutions, vitamins, and (7%) minerals Actual FX Volumes Prices M&A Ac

  7. Slide 7: Q1 2025 Animal Nutrition & Health

    Q1 2025 Animal Nutrition & Health Q1 2025 sales development • Continued improvement with higher profitability in the underlying business, further supported by the temporary 17% €874m vitamin price effect €746m 2% • Strong organic sales growth of 19%, with 17% higher prices (2%) ✓ Strong volume-led q

  8. Slide 8: Outlook 2025: Adjusted EBITDA of at least €2.4 billion

    Outlook 2025 Full year Adjusted EBITDA 2025 ‘housekeeping’ of at least €2.4 billion • D&A – around €225m/quarter • PPA adjustments - around €290m/year The FY 2025 outlook for the Group, is based on current business conditions and now includes an about €150 million contribution from the temporary • C

  9. Slide 9: Continuing our journey: 2025 plan

    Continuing our journey: 2025 plan • Acceleration of innovation and creation-led organic sales growth • Further synergies of about €100m Adj. EBITDA • Completion of vitamin transformation program with about €100m Adj. EBITDA • Exiting Animal Nutrition & Health and completing the tuning of our portfol

  10. Slide 10: Forward-looking statements

    This presentation contains forward-looking statements with respect to dsm-firmenich’s future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that

  11. Slide 11: We bring progress to life

    We bring progress to life © 2024 dsm-firmenich group.

dsm-firmenich — Q1 2025 Earnings Presentation on 6ix